Periorificial Dermatitis

General information

Chronic or recurrent inflammatory facial dermatosis characterized by a papulopustular eruption.
Primarily affects young to middle-aged women (20–45 years), although children and men may also be affected.
Predominantly involves the perioral, perinasal, and periocular regions.
Topical corticosteroids +++ are the strongest recognized association; rebound flaring may occur after withdrawal. Inhaled and intranasal corticosteroids may also contribute.
Other associated triggers include cosmetics, occlusive facial products, sunscreens, toothpaste/dental irritants, heat, wind, and UV exposure.
Epidermal barrier dysfunction and inflammation appear to contribute to pathogenesis.

Monomorphic 1 to 2 mm erythematous papules, sometimes papulovesicles or pustules.
Clustered on an erythematous background and may become confluent.
Fine scaling and dryness may occur.
No comedones +++, helping distinguish it from acne vulgaris.
Characteristic sparing of the skin immediately adjacent to the vermilion border +++, although this is not invariably present.

Primarily a clinical diagnosis.
No investigations are generally required for typical disease.
Culture ± KOH preparation when bacterial or fungal infection is suspected.
Patch testing when allergic contact dermatitis is suspected.
Biopsy is rarely required and is reserved for atypical or treatment-resistant presentations.

Begin with “zero therapy”: minimize facial products, particularly cosmetics and occlusive preparations. This alone may resolve mild disease.
Discontinue facial topical corticosteroids. Gradual tapering may be appropriate after prolonged/potent steroid exposure because abrupt withdrawal can produce a rebound flare. Do not restart the steroid because of the rebound.
Medically necessary inhaled or intranasal corticosteroids should not simply be discontinued; rinsing the face and mouth after use may reduce cutaneous exposure.
Mild/localized disease: topical metronidazole 0.75-1%, topical erythromycin, or pimecrolimus 1% BID, typically for several weeks.
Pimecrolimus may be particularly useful in corticosteroid-associated disease.
Moderate-to-severe, extensive, or refractory disease: an oral tetracycline, commonly doxycycline, generally for approximately 4-8 weeks, with duration individualized according to response.
Doxycycline is used primarily for its anti-inflammatory activity; adverse effects include photosensitivity, gastrointestinal upset, and pill esophagitis.
Avoid an automatic prolonged high-dose doxycycline → maintenance-dose regimen for every patient; treatment intensity and duration should be individualized, particularly because the overall evidence base for periorificial dermatitis therapy remains limited.
When tetracyclines are unsuitable, such as during pregnancy or in young children, erythromycin may be considered depending on the clinical context.

DermNet. Periorificial dermatitis (Perioral Dermatitis).
Acevedo-Fontanez LA, et al. Periorificial dermatitis: Pathophysiology, diagnosis, and management. J Am Acad Dermatol. 2026.
Gray NA, et al. Pharmacological interventions for periorificial (perioral) dermatitis in children and adults: a systematic review. J Eur Acad Dermatol Venereol. 2022;36(3):380–390.
Searle T, Ali FR, Al-Niaimi F. Perioral dermatitis: Diagnosis, proposed etiologies, and management. J Cosmet Dermatol. 2021;20(12):3839–3848.
Bolognia JL, Schaffer JV, Cerroni L. Dermatology. Elsevier.